United States Patent 4,496,537: Claims, Validity Risk, and US Landscape

US Patent 4,496,537 claims a lyophilization formulation method for high specific activity alpha-type interferon with enhanced biological stability, implemented by (i) buffering so the reconstituted solution pH stays in the range 6.5 to 8.0 and (ii) adding glycine or alanine at 5 to 150 mg/mL (per milliliter of water used for reconstitution). Dependent claims narrow to albumin co-addition (up to 10 mg/mL), specific interferon subtypes (alpha-1 or alpha-2), and specific buffer pH (about 7.0 to 7.4). The claim set is materially focused on excipient identity, excipient dosing, and the pH of the reconstituted solution after lyophilization.

What exactly does US 4,496,537 claim, and what is the operative technical limitation?

Claim 1: Core stability improvement architecture

Claim 1 is a method claim with three linked requirements:

Input: lyophilize a solution containing alpha-type interferon (high specific activity).
Buffer requirement: add a compatible buffer before lyophilization that maintains pH of the reconstituted solution within about 6.5 to 8.0.
Amino acid requirement: add glycine or alanine in an amount of 5 to 150 mg per milliliter of water to be added for reconstitution.
Stability outcome: the lyophilizate “substantially retains” biological activity after storage at 20°C for at least six months.

The legally operative constraints are: (a) interferon type (alpha-type), (b) reconstitution pH window, (c) glycine/alanine presence and dose expressed per mL water for reconstitution, and (d) six-month stability at 20°C as a functional result.

Claims 2, 4, 5, 6: Dependent narrowing points

Claim 2: up to 10 mg human albumin per mL of water used for reconstitution.
Claim 4: buffer maintains about 7.0 to 7.4 in the reconstituted solution.
Claim 5: for alpha-2 interferon, use ~5 to 25 mg glycine per 1×10^4 to 5×10^8 IU of the interferon mixture.
Claim 6: parallel range for ~5 to 25 mg alanine per 1×10^4 to 5×10^8 IU.
Claims 3 and 7: specify alpha-2 (claim 3) and alpha-1 (claim 7).

Practical implication for claim scope

The claim is not limited to a specific buffer species (it says “compatible buffer”); it is limited by the pH window in the reconstituted solution. Likewise, glycine/alanine dosing is limited by a per-reconstitution-water unit, which creates a measurable dosing boundary that is often easier to compare across candidate products than total mg per vial.

What are the enforceable claim elements most likely to drive infringement or invalidity?

Element A: “pH of the reconstituted solution” (6.5 to 8.0)

This is a process/formulation-moment limitation.
It can be probative in infringement because the pH is typically measurable after reconstitution.
It can be vulnerable in validity because many interferon lyophilization formulations historically used buffers to control pH.

Element B: Glycine or alanine at 5 to 150 mg/mL (per mL water for reconstitution)

This is specific and quantifiable.
It is also the most “composition-addition” like limitation in a method claim.
Validity risk rises if prior art discloses amino acid excipients for stabilization in lyophilized proteins within overlapping dose ranges.

Element C: Six months at 20°C with “substantially retains” biological activity

Functional outcome language can be litigated as indefiniteness, lack of written description, or lack of enablement if the patent record does not provide support across the full range.
It can also be used in infringement if the accused product has a comparable stability profile.

Element D: Alpha-1/alpha-2 interferon specificity in dependent claims

If prior art stabilization examples focus on interferon alpha-2 (or alpha-1), the dependent claims can be either stronger (if the prior art does not cover the same stabilizing approach) or weaker (if the same approach is already disclosed for those subtypes).

What does the claim landscape imply about novelty and obviousness risk?

Key concern: excipient and pH are “classic” formulation levers

The claim relies on:

buffers to control pH on reconstitution, and
glycine/alanine as stabilization excipients,
in a lyophilized interferon context.

Those components were widely used in early protein lyophilization stabilization strategies. A validity challenge would likely target whether it was already known to:

lyophilize interferon formulations,
add amino acids such as glycine/alanine,
buffer the reconstitution solution into the physiological-neutral range, and
achieve storage stability at non-refrigerated conditions.

How claim wording shapes obviousness arguments

Claim 1 uses broad “compatible buffer” language. If prior art discloses a buffer choice that produces a reconstituted pH within 6.5 to 8.0, the buffer element may be satisfied even if the buffer identity is different.
The glycine/alanine dose window (5 to 150 mg/mL) is broad. Overlap with prior art dose ranges can compress the novelty space.
The functional requirement (“substantially retains its biological activity even when stored at 20°C for at least six months”) helps differentiate if the applicant provided comparative stability data demonstrating an unexpected effect. Without a clear comparative basis spanning the full range, the limitation may be treated as routine optimization rather than a non-obvious step.

Secondary concern: dosing units and translational equivalence

For dependent claims 5 and 6, the range is tied to IU amounts of interferon mixture. An obviousness attack can argue that such scaling is formulaic, especially if prior art teaches mg-based excipient levels per IU for protein formulations.

What would a patent-claim strength assessment look like against generic lyophilized interferon formulations?

A practical way to stress-test claim coverage is to map the independent claim elements to common interferon product formulation patterns:

Claim requirement (US 4,496,537)	Typical in lyophilized protein products	Litigation impact
Buffer controls reconstitution pH	Common: buffers like phosphate, acetate, histidine, Tris derivatives	Infringement: usually met. Validity: can be anticipated.
Glycine or alanine excipient	Common: amino acids used as stabilizers/cryoprotectants	Infringement: depends on dose window. Validity: likely prior art overlap.
Dose 5 to 150 mg per mL reconstitution water	Not always disclosed with exact mg/mL-per-water unit	Validity: a close overlap is key. Infringement: measurable.
20°C for ≥ 6 months with biological activity retention	Often the differentiator in protein formulation patents	Infringement: requires stability evidence. Validity: depends on comparative data.

This combination tends to create a narrow novelty pocket unless the patent record demonstrates that the specific glycine/alanine dosing and pH coupling produces a non-obvious stability gain at 20°C.

What is the US patent landscape likely to include (and how it affects freedom-to-operate)?

Likely relevant families (high-level)

US patentability and FTO analysis for lyophilized interferon formulations typically intersects:

interferon stabilization and excipient selection (buffers, tonicity agents, bulking agents, amino acids, sugars),
lyophilization process parameters (cycle conditions, freezing conditions, annealing),
reconstitution conditions and the measured pH of the reconstituted solution,
specific interferon subtypes (alpha-1 vs alpha-2),
albumin or proteinaceous stabilizers (human albumin, gelatin, etc.).

US 4,496,537’s claims focus on items (1) and (3), with no explicit lyophilization-cycle parameter limitation in the independent claim. That shifts the competitive FTO risk toward formulations that match the same reconstitution pH and glycine/alanine dosing.

Likely “design-around” levers

Because claim 1 is limited to glycine or alanine specifically, FTO strategies often change one of the hard elements:

Replace glycine/alanine with another amino acid or stabilizer (e.g., other polyols/sugars), or
Use a buffer system that yields a reconstituted pH outside 6.5 to 8.0, or
Use a glycine/alanine dosing level outside 5 to 150 mg/mL (per mL reconstitution water), or
Remove human albumin if relying on claim 2 (dependent risk reduction).

Because the patent is method-based, structural “product form” similarity is less determinative than whether the manufacturing/reconstitution produces the claimed conditions.

How does the claim wording affect enforceability against “mix-and-match” formulation processes?

Buffer flexibility

Claim 1 does not name a buffer. If a competitor uses a different buffer but produces a reconstituted pH in 6.5 to 8.0, it can still land inside the literal scope.

Excipients added “prior to lyophilization”

The claim requires adding buffer and glycine/alanine “prior to lyophilization.” If a competitor lyophilizes interferon with a different matrix and only adds glycine/alanine upon reconstitution, literal infringement may be avoidable. The claim ties dosing to water used for reconstitution, but the addition is constrained to “prior to lyophilization.”

Interferon subtype mapping

Dependent claims 3 and 7 cover alpha-2 and alpha-1. If a competitor uses a different interferon type (non-alpha), dependent claims are inapplicable.

What are the principal litigation/validity themes likely to be applied to US 4,496,537?

1) Anticipation based on prior lyophilized interferon formulations

The most direct invalidity theory is anticipation if prior art discloses:

lyophilized alpha interferon,
buffer such that reconstituted pH is within 6.5 to 8.0, and
glycine or alanine at a comparable dose range for reconstitution,
with adequate stability at 20°C.

Even if prior art does not explicitly state “at least six months,” an examiner or challenger could argue disclosure of the same formulation system with implied stability expectations, depending on evidence norms for the jurisdiction and the patent record.

2) Obviousness as routine formulation optimization

If prior art teaches buffers and glycine/alanine separately, challengers may argue:

it would have been obvious to combine them, and
tuning within the broad ranges is routine optimization,
with stability at 20°C being the expected result of standard stabilization techniques.

3) Functional-result limitation vulnerability

“Substantially retains biological activity” after 20°C for six months is the improvement hook. If the specification does not include robust experimental coverage across the breadth of glycine/alanine and pH ranges, a challenger can argue that the functional outcome limitation is not credibly supported across the claimed scope.

Does the dependent claim structure create narrower “islands” of validity?

Yes. Dependent claims 5 and 6 add interferon-IU-normalized dosing ranges for glycine/alanine with alpha-2. This can create an island of narrower subject matter if prior art uses different dosing bases (e.g., fixed mg/vial or fixed molarity) and does not teach scaling per IU mixture.

Claim 4 narrows buffer performance to pH about 7.0 to 7.4. If prior art commonly uses buffers outside that range, claim 4 can reduce anticipation risk.

Claim 2 introduces human albumin co-addition up to 10 mg/mL of reconstitution water. If albumin is not widely combined with interferon and amino acid excipients in the same pH/glycine system, claim 2 can add a separate differentiating feature.

Key Takeaways

US 4,496,537 protects a lyophilized alpha interferon stabilization method defined by reconstituted-solution pH (6.5 to 8.0) plus glycine or alanine dose (5 to 150 mg/mL per mL reconstitution water), with a claimed stability at 20°C for at least six months.
The claims are strongest where competitors match the same measurable conditions (reconstitution pH and mg/mL-per-water dosing) and where stability evidence aligns with the “biological activity retention” outcome.
The validity profile is exposed because buffering and amino-acid excipients are widely used in protein lyophilization; the differentiation likely depends on demonstrating that the claimed ranges produce an unexpected stability improvement at 20°C rather than routine formulation optimization.
Dependent claims (alpha-1/alpha-2 specificity, pH about 7.0 to 7.4, albumin co-addition, and IU-normalized glycine/alanine dosing) create narrower paths that can reduce overlap with prior art but do not eliminate overlap risk if earlier filings disclosed similar systems.

FAQs

Is US 4,496,537 limited to a specific buffer type?
No. Claim 1 requires a “compatible buffer” that keeps the reconstituted pH within about 6.5 to 8.0; it does not specify buffer identity.
What excipients are central to infringement exposure?
Glycine or alanine at 5 to 150 mg per mL of reconstitution water, plus a buffer that yields reconstituted pH 6.5 to 8.0.
Does the patent require six-month stability at 20°C to be met?
Yes. Claim 1 includes the functional requirement that the lyophilizate substantially retains biological activity after at least six months at 20°C.
Do the dependent claims narrow exposure to interferon subtype?
Yes. Claim 3 covers alpha-2 interferon, and claim 7 covers alpha-1 interferon.
What are the most obvious design-around levers?
Change glycine/alanine (identity and/or dosing), shift the reconstituted pH outside the claimed window, or remove/add different components such as human albumin where relevant to dependent claim 2.

References

United States Patent 4,496,537, “Method for preparing a formulation of high specific activity alpha-type interferon having improved biological stability by lyophilizing a solution containing said alpha-type interferon,” claims 1-7.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	June 04, 1986	4,496,537	2003-09-16
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132		4,496,537	2003-09-16
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	Injection	103132		4,496,537	2003-09-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
South Africa	8209344	⤷ Start Trial
South Africa	8208580	⤷ Start Trial
Singapore	70687	⤷ Start Trial
Portugal	76013	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 4,496,537

Summary for Patent: 4,496,537